• The Academy has a profound duty to its members, the larger medical community and the public to ensure the integrity of all of its scientific, educational, advocacy and consumer information activities and materials. Thus each Academy Trustee, Secretary, committee Chair, committee member, taskforce chair, taskforce member, councilor, and representative to other organizations (“Academy Leader”), as well as the Academy staff and those responsible for organizing and presenting CME activities must disclose interactions with Companies and manage conflicts of interest or the appearance of conflicts of interest that affect this integrity. Where such conflicts or perceived conflicts exist, they must be appropriately and fully disclosed and resolved.

    All contributors to Academy educational and leadership activities must disclose all financial relationships (defined below) to the Academy annually. The ACCME requires the Academy to disclose the following to participants prior to the activity:

    • All financial relationships with Commercial Companies that contributors and their immediate family have had within the previous 12 months. A commercial company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
    • Meeting presenters, authors, contributors or reviewers who report they have no known financial relationships to disclose.

    The Academy will request disclosure information from meeting presenters, authors, contributors or reviewers, committee members, Board of Trustees, and others involved in Academy leadership activities (“Contributors”) annually. Disclosure information will be kept on file and used during the calendar year in which it was collected for all Academy activities. Updates to the disclosure information file should be made whenever there is a change. At the time of submission of a Journal article or materials for an educational activity or nomination to a leadership position, each Contributor should specifically review his/her statement on file and notify the Academy of any changes to his/her financial disclosures. These requirements apply to relationships that are in place at the time of or were in place 12 months preceding the presentation, publication submission, or nomination to a leadership position. Any financial relationship that may constitute a conflict of interest will be resolved prior to the delivery of the activity.

    Financial Relationship Disclosure

    For purposes of this disclosure, a known financial relationship is defined as any financial gain or expectancy of financial gain brought to the Contributor or the Contributor’s immediate family (defined as spouse, domestic partner, parent, child or spouse of child, or sibling or spouse of sibling of the Contributor) by:

    • Direct or indirect compensation;
    • Ownership of stock in the producing company;
    • Stock options and/or warrants in the producing company, even if they have not been exercised or they are not currently exercisable;
    • Financial support or funding to the investigator, including research support from government agencies (e.g., NIH), device manufacturers, and\or pharmaceutical companies; or
    • Involvement with any for-profit corporation that is likely to become involved in activities directly impacting the Academy where the Contributor or the Contributor’s family is a director or recipient of a grant from said entity, including consultant fees, honoraria, and funded travel.

    Description of Financial Interests

    Consultant / Advisor C Consultant fee, paid advisory boards or fees for attending a meeting.
    Employee E Employed by or received a W2 from a commercial company.
    Lecture Fees L Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company.
    Equity / Stock Owner O Equity ownership/stock options in publicly or privately traded firms, excluding mutual funds.
    Patents / Royalty P Patents and/or royalties for intellectual property.
    Grant Support S Grant support or other financial support to the investigator from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and\or pharmaceutical companies.

    Secretary for Annual Meeting

    Name Disclosure
    Maria M Aaron MD None

    Annual Meeting Program Committee

    The Annual Meeting Program Committee is responsible for the Academy's annual meeting Scientific Program, including Instruction Courses, Symposia, the Spotlight on Cataract, Scientific Papers/ePosters and Videos. Each subcommittee has five - ten reviewers who grade the instruction courses and paper/e-poster abstracts as well as three subcommittee members who review the grades, then select the courses and abstracts for presentation.

    Associate Secretary for the Annual Meeting Program Disclosure
    William J Fishkind MD FACS Bausch Lomb: C; Johnson & Johnson: C; Thieme Medical Publishers: P
    Annual Meeting Program Committee
    Nicole R Fram MD Aerie Pharmaceuticals, Inc.: C; Alcon Laboratories, Inc.: C,L; Allergan: C; Bausch Lomb: L; CorneaGen: C,O; Dompe: L; Johnson & Johnson Vision: C,L; Novartis Pharma AG: L; Ocular Science: C,O; Shire: L; Sun Pharmaceutical: L; W.L. Gore: C; Zeiss: C
    Bennie H Jeng MD Aquinox: C; EyeGate Pharmaceuticals Inc.: O; Jade therapeutics: C; Kedrion: C
    Steven J Gedde MD None
    Andrew G Lee MD None
    Julian D. Perry, MD Elsevier, Inc.: P; FDA Ophthalmic Devices Panel: C; Lacrimal Drainage Manometer Patent: P
    Hilda Capo MD None
    Ronald R Krueger MD Alcon Laboratories, Inc.: C; Calhoun Vision, Inc.: O; Johnson & Johnson Vision: C; Optoquest: C; Presbia: C; Strathespey Crown: O
    Sharon D Solomon MD None

    Subcommittee for: Cataract

    Chair Disclosure
    Nicole R Fram MD Aerie Pharmaceuticals, Inc.: C; Alcon Laboratories, Inc.: C,L; Allergan: C; Bausch Lomb: L; CorneaGen: C,O; Dompe: L; Johnson & Johnson Vision: C,L; Novartis Pharma AG: L; Ocular Science: C,O; Shire: L; Sun Pharmaceutical: L; W.L. Gore: C; Zeiss: C
    Subcommittee Members
    Surendra Basti MBBS Johnson & Johnson Vision: C; Shire Inc.: C
    Kevin M Miller MD Alcon Laboratories, Inc.: C; Bausch + Lomb: O; ianTECH/Zeiss: C; Johnson & Johnson Vision: C
    Subcommittee Reviewers
    Adi Abulafia MD Carl Zeiss Inc: L; Haag-Streit: L; Medicontur International SA: C; Oculus, Inc.: P
    Kourtney A Houser MD Alcon Laboratories, Inc.: C; Bausch + Lomb: C; CorneaGen: L; eyevance: C
    Susan M MacDonald MD Iantech: C,O; PERFECT LENS: C,O
    Steven M Naids MD Bausch + Lomb: L; Mallinckrodt Pharmaceuticals: L; NovaBay Pharmaceuticals: L
    Sathish Srinivasan MBBS AcuFocus, Inc.: C; Bausch Lomb: C; Medicontur: C; Scope Ophthalmics: C

    Subcommittee for: Cornea, External Disease

    Chair Disclosure
    Bennie H Jeng MD Aquinox: C; EyeGate Pharmaceuticals Inc.: O; Jade therapeutics: C; Kedrion: C
    Subcommittee Members
    Jessica B Ciralsky MD Abbott Medical Optics Inc.: C; Allergan: C; Shire: C
    Jennifer Y Li MD None
    Subcommittee Reviewers
    Marjan Farid MD Allergan: C; Bio-Tissue, Inc.: C; CorneaGen: C; Dompe: C; Eyepoint: C; Eyevance: C; Johnson & Johnson Vision: C; KALA: C; Shire: C
    Anat Galor MD Allergan: C; Dompe: C; Novaliq: C; Shire: C
    Douglas R Lazzaro MD None
    Wuqaas M Munir MD None
    Elmer Y Tu MD Abbvie: C; Eversight: S,E; Eye Bank Association of America: S; Kedrion: C; Okogen: C

    Subcommittee for: Glaucoma

    Chair Disclosure
    Steven J Gedde MD None
    Members
    Paula Anne Newman-Casey MD National Eye Institute: S
    Brian C Samuels MD PhD None
    Subcommittee Reviewers
    Shane J Havens MD None
    John T Lind MD Aerie Pharmaceuticals, Inc.: C,L; Allergan: C,L; Perrigo: S
    Veena Rao MD None
    Sarah Van Tassel MD New World Medical Inc: L

    Subcommittee for: Neuro-Ophthalmology, Electronic Health Records/Information Technology, Ethics, General Medical, Global Ophthalmology, Medical Education, Ophthalmic History and Vision Rehabilitation

    Chair Disclosure
    Andrew G Lee MD None
    Members
    Julie Falardeau MD None
    Kenneth S Shindler MD PhD FM Kirby Foundation: S; National Eye Institute: S; Noveome Biotherapeutics, Inc.: C,S; RPB: S; UpToDate: P
    Reviewers
    John J Chen MD PhD None
    Courtney E Francis MD None
    Clare Louise Fraser MBBS None
    Susan M Ksiazek MD None
    Y Joyce Liao MD PhD None

    Subcommittee for: Ocular Pathology, Oncology and Oculoplastics, Orbit

    Chair Disclosure
    Julian D Perry Elsevier, Inc.: P; FDA Ophthalmic Devices Panel: C; Lacrimal Drainage Manometer Patent: P
    Members
    Jonathan W Kim MD None
    Sara T Wester MD Horizon Therapeutics: C
    Reviewers
    Malena M Amato MD None
    Steven M Couch MD None
    Santosh G Honavar MD None
    Bradford William Lee MD MSC None
    Lily Koo Lin MD None

    Subcommittee for: Pediatric Ophthalmology, Strabismus

    Chair Disclosure
    Hilda Capo MD None
    Members
    Martha P Schatz MD None
    Federico G Velez MD None
    Reviewers
    David K Coats MD None
    Ramesh Kekunnaya MD FRCS None
    Stacy L Pineles MD Fitz Frames: C
    Tina Rutar MD Sydnexis: S
    Mitchell B Strominger MD None

    Subcommittee for: Optics, Refraction, Contact Lenses, and Refractive Sugery

    Chair Disclosure
    Ronald R Krueger MD Alcon Laboratories, Inc.: C; Calhoun Vision, Inc.: O; Johnson & Johnson Vision: C; Optoquest: C; Presbia: C; Strathespey Crown: O
    Members
    J Bradley Randleman MD None
    Elizabeth Yeu MD Alcon Laboratories, Inc.: C,L; Allergan: C,L; ArcScan: C; Bausch + Lomb: C; Bausch Lomb: C; Bio-Tissue, Inc.: C,L; Carl Zeiss Meditec: C,L; Glaukos Corporation: C,L; Innovation Labs: O; iOptics: C,S; Johnson & Johnson Vision: C,L; Kala: C,S; Katena Products, Inc: C; Modernizing Medicine: O; Novartis, Alcon Pharmaceuticals: C; Ocular Science: C,O; OcuSoft: C; Omeros: L; ScienceBased Health: C; Shire: C,L; Sight Sciences: C; Sun Ophthalmics: L; TearLab: C; TearScience: C; TissueTech, Inc.: C,L; Topcon Medical Systems Inc.: S; TopCon: S
    Reviewers
    Kendall E Donaldson MD Alcon Laboratories, Inc.: C,L; Allergan: C; Eyevance: C; Johnson and Johnson: C; Kala: C; Omeros: C; Shire: C; SUN: C
    Brad E Kligman MD None
    Edward E Manche MD Alcon Laboratories, Inc.: S; Allergan: S; Averdro: C,S; Best Doctors, Inc.: C; Carl Zeiss Inc: C,S; Clarity Vision Technologies: O,C; Guidepoint: C; Johnson & Johnson Vision: C,S; Ocular Therapeutix: S; Presbia, Inc.: S; RxSight: O; Shire: C; Vacu-Site: O,P
    Jodhbir S Mehta MBBS PhD None

    Subcommittee for: Retina, Vitreous and Uveitis, Intraocular Inflammation

    Chair Disclosure
    Sharon D Solomon MD None
    Members
    Sunir J Garg MD FACS Department of Biotechnology, Government of India: S; Indian Council of Medical Research: S; Medical Research Council, UK: S; Santen, Inc.: C; Wellcome Trust: S
    Shlomit Schaal MD PhD None
    Reviewers
    Anita Agarwal MD None
    Bryn M Burkholder MD None
    Roomasa Channa, MD None
    Muge R Kesen MD AbbVie: L
    Aleksandra Rachitskaya MD Alcon Laboratories, Inc.: C; Allergan: C; Novartis Pharma AG: L; Second Sight Medical Products: C; Zeiss: C
    Ashvini K Reddy MD Clearside: C
    Amy C Schefler MD Allergan: C; Aura Biosciences: S; Castle Biosciences: S; GENENTECH: C,S; Regeneron Pharmaceuticals, Inc.: S
    Lucia Sobrin MD None
    Nadia Khalida Waheed MD Bayer Healthcare Pharmaceuticals: S; Carl Zeiss Meditec: S,C; GENENTECH: C; Heidelberg Engineering: C; Johnson & Johnson: C,S; Nidek, Inc.: S; Ocudyne: O; Optovue: C,L; Regeneron Pharmaceuticals, Inc.: C,S; Topcon Medical Systems Inc.: C
    Adam S Wenick MD None

    Special Projects Committee

    The Special Projects Committee is responsible for developing programming and formats that cross subspecialties, as well as complement those that are submitted by members or societies.

    Associate Secretary Disclosure
    Rick E Palmon MD None
    Members
    Daniel H Chang MD AcuFocus, Inc.: S; Allergan: C,S; Carl Zeiss Meditec: C,L; ClarVista Medical: C; Johnson & Johnson Vision: C,L,S; Mynosys Cellular Devices: C,S; Omega Ophthalmics: C,O
    Laura B Enyedi MD None
    Carolyn K Pan MD None
    Rachel K Sobel MD None
    Nicholas J Volpe MD Opthotech: C; Opticent Inc.: O; Quark Pharmaceuticals: S
    Sarah Wellik MD None

    Skills Transfer Advisory Committee

    The Skills Transfer Advisory Committee is responsible for selecting the Skills Transfer courses and labs.

    Associate Secretary Disclosure
    Jack A Cohen MD FACS None
    Members
    Deepinder K Dhaliwal MD Avedro, Inc.: S; CorneaGen: L; Johnson & Johnson: C; Novaliq: C; Noveome: S; Ocular Therapeutix: L; Shire: L,S; STAAR Surgical: L; Trefoil: C
    Brian A Francis MD Allergan, Inc.: C,S; Bausch + Lomb: C; Diopsys: C,S; Endo Optiks, Inc.: C; Glaukos Corporation: C; Innfocus: S; NeoMedix Corporation: C
    Sumit Garg MD Aerie Pharmaceuticals, Inc.: C; Allergan, Inc.: C; Avedro, Inc.: C; EyePoint: C; Eyevance: C; Johnson & Johnson Vision: C; Kala: C; New World Medical Inc: C; OcuTrx: O; Shire/Takeda: C,L; SightLife Surgical: C; Verana Health: C; Vision Care Inc.: C; Zeiss: C
    Jill S Melicher Larson MD SLACK: P; Unifeye Vision Partners: O; Zift Medical: O
    Michael L Savitt MD None
    Anjali Tannan MD None

    2019 Subspecialty Day Advisory Committee

    Associate Secretary Disclosure
    Daniel S Durrie MD AcuFocus, Inc.: C,O; Alcon Laboratories, Inc.: C; Alphaeon: O; Avedro: C,L,O; Concierge Key Health: O,C; Eyegate Pharma: C; Hoopes Durrie Rivera Research Center : C; iOR Holdings: O; iOR Partners: O; Johnson & Johnson Vision : C,L; Strathspey Crown LLC : O
    Members
    Maria M Aaron MD None
    Julia A Haller MD Aura Biosciences: C; Celgene: O; KalVista: C; Lowy Medical Research Institute: C; Novartis Pharmaceuticals Corporation: C
    Shahzad I Mian MD National Eye Institute: S
    R Michael Siatkowski MD None
    Kuldev Singh MD aerie: C; Aerpio: C; Alcon Laboratories, Inc.: C; Allergan: C; Belkin Laser Ltd: C; Glaukos Corporation: C; Graybug: C; InjectSense: C; Ivantis: C; Johnson & Johnson: C; Mynosys: C; National Eye Institute: S; Novartis Institute for Biomedical Research: C; Ocular Therapeutix, Inc.: C; Santen, Inc.: C; Shire: C; Thieme Medical Publishers: C; U.S. Food and Drug Administration: C,S

    2018 AAOE Content Committee

    The AAOE Annual Meeting Program Committee is responsible for selecting the AAOE Instruction Courses, Coding Sessions and the Practice Management Master Classes.

    Chair Disclosure
    Natalie M Loyacano COMT OCS None
    Members
    Jeffrey Brust MBA None
    Stephanie R Collins COA Novartis, Alcon Pharmaceuticals: C; Regeneron Pharmaceuticals, Inc.: C,L
    Brett D Gerwin MD None
    Sean D Goodale CPA MBA GENENTECH: C,L; Novartis Pharma AG: C; Regeneron: C,L
    Ann M Hulett CMPE None
    Anthony Pruett Johnson MD FACS None
    Nicole E Kesten None
    Julia Lee JD Modernizing Medicine: C
    Jennifer L Lehman None
    Amanda Mestler COT None
    Arvind Saini MD MBA None
    JoAnne Smagacz None

    Academy Staff

    Name Disclosure
    Debra Rosencrance None
    Melanie Rafaty None
    Sangeeta Fernandes None
    Susan Oslar None
    Ann L'Estrange None
    Elizabeth Washburn None
    Licia Wells None
    Julia Fennell None
    Sadie Peckens None
    Carolyn Little None